Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Profiling 1,502 biliary cancers on one commercial platform, gallbladder tumours stood out for HER2 overexpression and amplification and for defects in homologous recombination repair, and, with intrahepatic tumours, for more immunotherapy markers than extrahepatic disease.
Overview
1,502 biliary tract cancers were profiled using next-generation sequencing, immunohistochemistry, in situ hybridisation and RNA sequencing to compare intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder carcinoma, which are frequently grouped together in trials despite differences in tumour biology.
Intrahepatic tumours had higher rates of IDH1, BAP1 and PBRM1 mutations and FGFR2 fusions; extrahepatic tumours higher rates of KRAS, CDKN2A and BRCA1 mutations; and gallbladder carcinomas higher rates of homologous recombination repair deficiency and HER2 overexpression and amplification. Intrahepatic and gallbladder tumours had higher rates of potential positive predictive biomarkers for immune checkpoint inhibition (PD-L1 expression, high microsatellite instability and high tumour mutational burden) than extrahepatic tumours.
- Gallbladder carcinoma had the highest rates of HER2 overexpression and amplification and of homologous recombination repair deficiency among the three biliary sites.
- Intrahepatic and gallbladder tumours carried more PD-L1 expression, MSI-high and TMB-high than extrahepatic tumours.
- Intrahepatic tumours: IDH1, BAP1, PBRM1 and FGFR2 fusions; extrahepatic: KRAS, CDKN2A, BRCA1.
The largest single-platform comparison; the abstract gives directions rather than percentages, so the figures on OnCo come from the other cohorts, but it supports testing gallbladder cancer for HER2, repair defects and immunotherapy markers.
- Abstract reports relative rates, not frequencies; the full paper holds the numbers.
- Referral cohort profiled by Caris Life Sciences.
Similar pages
not linked directly; found by shared links- Key paperMismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma
Shares Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
- Key paperGenomic profiling of Indian gallbladder carcinoma: mutational insights in a high-incidence population
Shares Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), HER2.
- TrialKEYNOTE-158
Shares Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
- PersonSabine Linn
Shares Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD).
- TermHER2 and genomic testing for biliary cancer on the NHS
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), HER2, Gallbladder cancer.
- TermMicrosatellite-stable (MSS) / mismatch-repair proficient (pMMR)
Shares Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
- Key paperThe mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population
Shares BRCA1 / BRCA2 (HRD), HER2, Gallbladder cancer.
- Key paperGenomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
Shares Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.